Now available HERCESSI™

HERCESSI™ (trastuzumab-strf) is a HER2/neu receptor antagonist indicated in adults for:

• The treatment of HER2-overexpressing breast cancer.
• The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

Please see full prescribing information here.